Microfluidic Gut-liver chip for reproducing the first pass metabolism

Area of Science:

• Pharmacology
• Bioengineering
• Toxicology

Background:

• First-pass metabolism in the gut and liver significantly impacts oral drug efficacy and safety.
• In vitro modeling of first-pass metabolism is challenging due to complex simultaneous processes.
• Conventional cell culture systems struggle to replicate the integrated gut-liver system.

Purpose of the Study:

• To develop and validate a microfluidic gut-liver chip for in vitro first-pass metabolism studies.
• To create a platform that sequentially models drug absorption in the gut and metabolism in the liver.
• To assess the chip's ability to accurately predict drug metabolic profiles.

Main Methods:

• Fabrication of a microfluidic chip with separate gut epithelial (Caco-2) and liver (HepG2) cell culture layers.
• Co-culture of Caco-2 and HepG2 cells within the microfluidic device.
• Assessment of cellular physiological functions, including cytochrome P450 activity and Caco-2 absorptive properties.
• Evaluation of the chip's performance using apigenin as a model compound for first-pass metabolism.

Main Results:

• Successful co-culture of Caco-2 and HepG2 cells on the microfluidic chip.
• Enhanced cytochrome P450 metabolic activity in both cell types when cultured on chip.
• Altered absorptive properties of Caco-2 cells due to fluid flow.
• Apigenin's metabolic profile on the chip more closely resembled in vivo data compared to monoculture.

Conclusions:

• The developed microfluidic gut-liver chip effectively reproduces key aspects of first-pass metabolism.
• This platform offers a more physiologically relevant in vitro model for drug metabolism studies.
• The chip has the potential to improve preclinical drug evaluation by providing accurate metabolic insights.